Clinical Scorecard: FDA Approves Device for Pancreas Care
At a Glance
| Category | Detail |
|---|---|
| Condition | Locally Advanced Pancreatic Cancer |
| Key Mechanisms | Tumor Treating Fields disrupt cancer cell division and survival. |
| Target Population | Adult patients with locally advanced pancreatic cancer. |
| Care Setting | Outpatient and home-based care. |
Key Highlights
- Optune Pax approved for use with gemcitabine and nab-paclitaxel.
- Median overall survival increased to 16 months with Optune Pax vs 14 months without.
- One-year survival rates were 68% with Optune Pax vs 60% control.
- Device-related skin adverse events occurred in 76% of treated patients.
- First new FDA-approved treatment for locally advanced pancreatic cancer in nearly 30 years.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of locally advanced pancreatic cancer should be confirmed through imaging and biopsy.
Management
- Optune Pax should be used in conjunction with gemcitabine and nab-paclitaxel.
Monitoring & Follow-up
- Monitor for device-related skin adverse events and overall patient well-being.
Risks
- Device-related skin adverse events are common but generally mild (grade 1 or 2).
Patient & Prescribing Data
571 patients enrolled in the PANOVA-3 trial.
Optune Pax improves overall survival and extends time to pain progression without increasing systemic toxicity.
Clinical Best Practices
- Train patients on device placement and operation prior to use.
- Integrate Optune Pax into daily life for enhanced patient compliance.
Related Resources & Content
- Journal of Clinical Oncology
- US Food and Drug Administration
- National Cancer Institute: Cancer Stat Facts - Pancreatic Cancer
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
